Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492582 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,499
- Enrollment target
NCT01492582 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1,499 participants.
The verdict
NCT01492582, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,499 participants
- Enrollment target
Study Summary
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.
Interventions
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- OTHER survey administration
- BIOLOGICAL quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,499 participants |
| Start Date | 2012-07 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492582
The ClinicalTrials.gov registry entry for NCT01492582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01492582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01492582 about?
NCT01492582 is a clinical study titled "Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors". This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadri...
What is the current status of trial NCT01492582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,499 participants. The study started on 2012-07. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT01492582?
The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), survey administration (OTHER), quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01492582?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.